jCyte Inc. Announces First Patients Treated in JC02-88 Trial for Retinitis Pigmentosa
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study evaluating the safety and efficacy of jCell (famzer...
How does jCell’s mechanism and dosing strategy compare with other gene‑ or cell‑based therapies targeting retinitis pigmentosa in terms of efficacy, safety, and market size?
What is the expected timeline for data readout from this trial, and how could that timeline align with upcoming FDA interactions or potential partnership announcements?
How might the initiation of the JC02-88 trial and the higher cell dose affect JCyte's short‑term stock volatility and valuation multiples?
2 days ago